Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus.
about
Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for interventionUniversal newborn screening for congenital CMV infection: what is the evidence of potential benefit?Viral infections during pregnancyViral infections of the fetus and newborn infantSeroprevalence of cytomegalovirus infection in the United States, 1988-1994Predictive factors of cytomegalovirus seropositivity among pregnant women in Paris, FranceInfection of cells with human cytomegalovirus during S phase results in a blockade to immediate-early gene expression that can be overcome by inhibition of the proteasome.Risk factors for and clinical outcome of congenital cytomegalovirus infection in a peri-urban West-African birth cohort.Symptomatic infant characteristics of congenital cytomegalovirus disease in Australia.A haemophagocytic lymphohistiocytosis (HLH)-like picture following breastmilk transmitted cytomegalovirus infection in a preterm infant.Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challengeGuidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerCongenital cytomegalovirus mortality in the United States, 1990-2006.B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies.A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virusDiagnosis of and screening for cytomegalovirus infection in pregnant women.Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant.Real-time PCR quantification of human cytomegalovirus DNA in amniotic fluid samples from mothers with primary infection.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theHuman cytomegalovirus transmission from the uterus to the placenta correlates with the presence of pathogenic bacteria and maternal immunityPrevention of maternal cytomegalovirus infection: current status and future prospects.Cytomegalovirus viruria and DNAemia in healthy seropositive women.Experimental coinfection of rhesus macaques with rhesus cytomegalovirus and simian immunodeficiency virus: pathogenesisRecent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases.Progress toward an elusive goal: current status of cytomegalovirus vaccines.Development of a cytomegalovirus vaccine: lessons from recent clinical trials.HCMV-infected cells maintain efficient nucleotide excision repair of the viral genome while abrogating repair of the host genome.Human cytomegalovirus terminase as a target for antiviral chemotherapy.Specific chromosome 1 breaks induced by human cytomegalovirus.Seroprevalence of Cytomegalovirus among pregnant women and hospitalized children in PalestineCyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.Urine polymerase chain reaction as a screening tool for the detection of congenital cytomegalovirus infectionKnowledge and awareness of congenital cytomegalovirus among womenInfluence of maternal infections on neonatal acute phase proteins and their interaction in the development of non-affective psychosisCongenital cytomegalovirus infection: clinical outcomeCytomegalovirus infection in pregnancy: review of the literaturePrediction of Maternal Cytomegalovirus Serostatus in Early Pregnancy: A Retrospective Analysis in Western Europe.Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy.Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.Primary versus nonprimary cytomegalovirus infection during pregnancy, Israel.
P2860
Q24570124-4DAF2CAC-6D06-40F1-857F-0EBC1C355295Q26824199-8B553717-9E38-476A-84EB-5171A03CE0DCQ27027087-CB1EE63D-912E-4707-90D5-24BA91E42ED1Q27488781-8FAD73CC-FC0C-4F41-B5A0-FE52A0940D0BQ28267544-2881ED63-6CB8-45A9-80E5-50224FCA5BA2Q30359694-3F636274-A066-4CE4-9102-646D5BED23D6Q30703512-95159389-6397-4ECF-9ECF-DC310D3E8E0AQ33286814-9C54B245-E33D-4D98-8A59-6C9A449C5C12Q33367852-99B2ECCF-A495-4967-BAB2-C145DC174FE8Q33374591-65F83D5D-CA77-444A-8472-C3CD17684166Q33551402-60E89B69-0138-4F7E-A74C-962B6FB2F47FQ33650105-9131D3A8-02A1-4BEB-91FD-BC0CDEE532ADQ33889500-6319B775-4B34-4C22-995C-139AAE0503E8Q33996614-F74A6D1C-CFF8-415A-A905-D1BE8AC88D32Q34000122-65D07F82-F691-4CF2-A6AB-37B5E3279CCFQ34042125-E3216DAB-608B-4B16-BB94-D9020D9EB52BQ34102747-84AC3B6F-5115-4155-A744-966D26D8D254Q34193292-9474613A-D337-4A0D-B168-B2321BB44C43Q34212799-20B6D59E-C0DE-466C-AD96-7D0FBF4C98D2Q34227634-7A9C1C78-1D6B-4D61-99A3-28C0173805A4Q34272089-137E9B1E-057B-414B-9A7F-68D66A24F341Q34332584-CFA3691A-0756-4BB3-A17D-975FD73B120DQ34343874-7BAE03AB-48D6-4C36-965D-0A8E5B495243Q34349745-E5A8D952-8140-4BD7-98E5-8F3E167A1420Q34434818-1B89200F-C437-4334-A6BB-5BEDADBB171EQ34451960-6A48E9FC-28B4-4967-8DA7-DF19B76E5BDEQ34499369-D07AC41F-5922-403C-AFB6-38F8EAAA0FECQ34580776-DF72EF48-242A-4EF7-B656-0B13F6E1CDEAQ34979943-D67B5A47-C1AB-4537-B0A1-15BC1C7E6D9DQ35037239-4627A8A0-6CAC-438E-9E38-8A2E40C8291BQ35270303-BA80FB3B-2150-43FB-96B9-7B5111E0DDA7Q35293960-EC92695F-D5F9-4DDE-B962-BCFCCB0C0B16Q35606135-2B2C2E7F-96EB-4153-862B-7ECE1CFB7359Q35653822-BD76D40F-40D5-453D-AC0C-12F7F90316B6Q35753496-0FAA6787-A098-4731-9619-4CC4923D1656Q35755969-4D820E8F-638A-4689-B925-98EFCA636F6FQ35875262-921B317F-09DF-4A90-B7E4-54F67AAA20E0Q35917421-B8E7D4A2-A6CA-4DB8-98B2-A759D14E9D83Q35946943-7DBC0329-C5FA-4E27-9A6A-6BD0F193C713Q36034069-FF2F33F5-28B0-4DE3-B750-F17B427FC56A
P2860
Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Symptomatic congenital cytomeg ...... g immunity to cytomegalovirus.
@en
type
label
Symptomatic congenital cytomeg ...... g immunity to cytomegalovirus.
@en
prefLabel
Symptomatic congenital cytomeg ...... g immunity to cytomegalovirus.
@en
P2093
P356
P1433
P1476
Symptomatic congenital cytomeg ...... g immunity to cytomegalovirus.
@en
P2093
P356
10.1542/PEDS.104.1.55
P407
P433
P577
1999-07-01T00:00:00Z